Oneill Ref

“Recent Advances in Antifungal Drug Development” February 2, 2006 Jennifer O’Neill Background: Andriole VT, “Current and future antifungal therapy: new targets for antifungal agents,” J. Antimicrob. Chemother. 1999, 44, 151–62. Boucher HW, Groll AH, Chiou CC, Walsh TJ, “Newer Systemic Antifungal Agents: Pharmacokinetics, Safety and Efficacy,” Drugs 2004, 64(18), 1997–2020. de Pauw BE, Meunier F, “The Challenge of Invasive Fungal Infection,” Chemotherapy 1999, 45, 1–14. Georgopapdakou NH, Walsh TJ, “Antifungal Agents: Chemotherapeutic Targets and Immunologic Strategies,” Antimicrob. Agents Ch. 1996, 40, 279–91. Ghannoum MA, Rice LB, “Antifungal Agents: Mode of Action, Mechanisms of Resistance, and Correlation of these Mechanisms with Bacterial Resistance,” Clin. Microbiol. Rev. 1999, 12(4), 501–517. Groll AH, Walsh, TJ, “Antifungal chemotherapy: advances and perspectives,” Swiss Med. Wkly. 2002, 132, 303–11. Hope W, Morton A, Eisen DP, “Increase in prevalence of nosocomial non-Candida albicans candiaemia and the association of Candida krusei with fluconazole use,” J. Hosp. Infect. 2002, 50, 56–65. Klepser ME, “Future Candidates in the Search for New Antifungal Agents,” Current Treatment Options in Infectious Diseases 2003, 5, 489–94. Milhaud J, Ponsinet V, Takashi M, Michels B, “Interactions of the drug amphotericin B with phospholipids membranes containing or not ergosterol: new insight into the role of ergosterol,” Biochim. Biophys. Acta 2002, 1558, 95–108. Tournu H, Van Dijck P, “Fungal Pathogens Research: Novel and Improved Molecular Approaches for the Discovery of Antifungal Drug Targets,” Curr. Drug Targets 2005, 6, 909–22. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP, “Secular Trend of HospitalAcquired Candidemia among Intensive Care Unit Patients in the United Sates during 1989–1999,” Clin. Infect. Dis. 2002, 35, 627–630.

Azoles: Bartroli J, Turmo E, Alguero M, Boncompte E, Vericat ML, Coute L, Ramis J, Merlos M, Garcia-Rafanell J, Forn J, “New Azole Antifungals. 3. Synthesis and Antifungal Activity of 3-Substituted-4(3H)-quinazolinones,” J. Med. Chem. 1998, 41, 1869–82. Di Santo R, Tafi A, Costi R, Botta M, Artico M, Corelli F, Forte M, Caporuscio F, Angiolella L, Palamara AT, “Antifungal Agents. 11. N-Substituted Derivatives of 1[(Aryl)(4-aryl-1H-pyrrol-3yl)methyl]-1H imidazole: Synthesis, Anti-Candida Activity, and QSAR Studies,” J. Med. Chem. 2005, 48, 5140–53. Dickinson RF, Bell AS, Hitchcock CA, Narayanaswami S, Rey SJ, Richardson K, Troke PF, “Novel antifungal 2-aryl-1(1H-1,2,4-triazol-1-yl)butan-2-ol derivatives with high activity against Aspergillus fumigatus,” Bioorg. Med. Chem. Lett. 1996, 6(16), 2031–6. Koltin Y, Hitchcock CA, “The search for new triazole antifungal agents,” Curr. Opin. Chem. Biol. 1997, 1(2) 176–82. Pfizer Inc. VFEND® Complete Product Information, March 2005. Podust LM, Poulos TL, Waterman MR, “Crystal structure of cytochrome P450 14αsterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors,” PNAS 2001, 98(6), 3068–73. Racette AJ, Roenigk HH, Hansen R, Mendelson D, Park A, “Photoaging and phototoxicity form long-term voriconazole treatment in a 15-year-old girl,” J. Am. Acad. Dermatol. 2005, 52(5) S81–5. Sheehan DJ, Hitchcock CA, Sibley CM, “Current and Emerging Azole Antifungal Agents,” Clin. Microbiol. Rev. 1999, 12(1), 40–79.

Echinocandins: Arikan S, Paetznick V, Rex JH, “Comparative Evaluation of Disk Diffusion with Microdilution Assay in Susceptibility Testing of Caspofungin against Aspergillus and Fusarium Isolates,” Antimicrob. Agents Ch. 2002, 46(9), 3084–7. Aszodi J, Fauveau , Melon-Manguer D, Ehlers E, Schio L, “Synthesis of new echinocandin derivatives via a diol-keto transposition,” Tetrahedron Lett. 2002, 43, 2953–6. Barret D, “From natural products to clinically useful antifungals,” Biochim. Biophys. Acta 2002, 1587, 224–33.

Bouffard FA, Zambias RA, Dropinski JF, Balkovec JM, Hammond ML, Abruzzo GK, Bartizol KF, Marrinan JA, Kurtz MB, McFadden KH, Nollstadt KH, Powles MA, Schmatz DM, “Synthesis and Antifungal Activity of Novel Cationic Pneumocandin Bo Derivatives,” J. Med. Chem. 1994, 37, 222–5. Carver PL, “Micafungin,” Ann. Pharmacother. 2004, 38, 1707–21. Chandrasekar PH, Manavathu EK, “Caspofungin,” Drugs Today 2002, 38(12), 829–46. Debono J, Turner WW, LaGrandeur L, Burkhardt FJ, Nissen JS, Nichols KK, Rodriuez MJ, Zweifel MJ, Zeckner DJ, Gordee RS, Tang J, Parr TR, “Semisynthetic Chemical Modification of the Antifungal Lipopeptide Echinocandin B (ECB): Structure-Activity Studies of the Lipophilic and Geometric Parameters of Polyarylated Acyl Analogs of ECB,” J. Med. Chem. 1995, 38, 3271–81. Fujie A, Iwamoto T, Sato B, Murmatsu H, Kasahara C, Furuta T, Hori Y, Hino M, Hashimoto S, “FR131535, a Novel Water-Soluble Echinocandin-Like Lipopeptide: Synthesis and Biological Properties,” Bioorg, Med. Chem. Lett. 2001, 11, 399–402. Journet M, Cai D, DiMichele LM, Highes DL, Larsen RD, Verhoeven TR, Reider PJ, “Semisynthesis of an Antifungal Lipopeptide Echinocandin,” J. Org. Chem. 1999, 64, 2411–7. Letscher-Bru V, Herbrecht R, “Caspofungin: the first representative of a new antifungal class,” J. Antimicrob. Chemother. 2003, 51, 513–21. Sawistowska-Schroder ET, Kerridge D, Perry H, “Echinocandin inhibition of 1,3-β-Dglucan synthase from Candida albicans,” FEBS Lett. 1984,173(1), 134–8. Wang W, Li Q, Hasvold L, Steiner B, Dickman DA, Ding H, Clairborne A, Chen H-J, Frost D, Goldman RC, Marsh K, Hui Y-H, Cox B, Nilius A, Balli D, Lartey P, Plattner JJ, Bennani YL, “Discovery, SAR, Synthesis, Pharmacokinetic and Biochemical Characterization of A-192411: A Novel Fungicidal Lipopeptide-(I),” Bioorg. Med. Chem. Lett. 2003, 489–93. Zambias RA, Hammond ML, Heck JV, Bartizal K, Trainor C, Abruzzo GK, Schmatz DM, Nollstadt KM, “Preparation and Structure-Activity Relationships of Simplified Analogues of the Antifungal Agent Cilofungin: A Total Synthesis Approach,” J. Med. Chem. 1993, 35, 2843–55. Zambias RA, James C, Hammond ML, Abruzzo GK, Bartizal KF, Nollstadt KH, Douglas C, Marrinan J, Balkovec JM, “Antifungal Lipopeptides: Structure-Activity Relationships of 3-hydroxyglutamine-modified Pneumocandin Bo Derivatives,” Bioorg. Med. Chem. Lett. 1995, 5(20), 2357–62.

Future Targets: Bareich DC, Nazi I, Wright GD, “Simultaneous In Vitro Assay of the First Four Enzymes in the Fungal Aspartate Pathway Identifies a New Class of Aspartate Kinase Inhibitor,” Chem. Biol. 2003, 10, 967–73. DeLaBarre B, Thompson PR, Wright GD, Berghuis AM, “Crystal structures of homoserine dehydrogenase suggest a novel catalytic mechanism for oxidoreductases,” Nat. Struct. Biol. 2000, 7(3), 238–44. Ferguson AD, Hofmann E, Coulton JW, Diedrichs K, Welte W, “Siderophore-Mediated Iron Transport: Crystal Structure with Bound Lipopolysaccharide,” Science 1998, 282, 2215–20. Hissen AHT, Wan ANC, Warwas ML, Pinto LJ, Moore MM, “The Aspergillus fumigatus Siderophore Biosynthetic Gene sidA, Encoding L-Ornithine N5-Oxygense, is Required for Virulence,” Infect. Immun. 2005, 73(9), 5493–503. Jacques SL, Mirza IA, Ejim L, Koteva K, Hughes DW, Green K, Kinach R, Honek JF, Lai HK, Berghuis AM, Wright GD, “Enzyme-Assisted Suicide: HON inhibitor of HSD,” Chem. Biol. 2003, 10, 989–95. Schrettl M, Binell E, Kragl C, Joech C, Rogers T, Arst HN, Haynes K, Haas H, “Siderophore biosynthesis but not reductive iron assimilation is essential for Aspergillus fumigatus virulence,” J. Exp. Med. 2004, 200, 1213–9. Winkelman G, “Metal Transport,” Biometals 2002, 30(4), 691–6.

Web resources: [email protected] http://www.centerwatch.com/patient/drugs/DRUGLIST.html http://www.pharma.org/newmedicines/ www.doctorfungus.com “New analysis supports starting with VFEND for life-threatening fungal infections,” 30 OCT 2005 http://www.medical newstoday.com/medicalnews.php?newid-32621